Soligenix, Inc. Press Releases

Get SNGX Alerts
*Delayed - data as of Oct. 20, 2014 14:23 ET  -  Find a broker to begin trading SNGX now

Community Rating:
View:    SNGX Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00
9/24/2014 9:00:00 AM - Market Wire

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
9/23/2014 7:00:00 AM - PR Newswire

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine
9/19/2014 7:00:00 AM - PR Newswire

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
9/17/2014 7:00:00 AM - PR Newswire

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology
9/9/2014 7:00:00 AM - PR Newswire

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
9/8/2014 7:00:00 AM - PR Newswire

Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program
9/5/2014 7:00:00 AM - PR Newswire

Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine
9/2/2014 7:00:00 AM - PR Newswire

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
8/11/2014 7:30:00 AM - PR Newswire

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™
8/7/2014 7:00:00 AM - PR Newswire

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
8/1/2014 7:30:00 AM - PR Newswire